Microsoft Exchange Server

EQS-News: DEFENCE’S ACCUTOX ANTI-CANCER ARM-002 VACCINE EXHIBITS POTENT ANTIGEN PRESENTATION

Retrieved on: 
金曜日, 5月 3, 2024
Vaccination, DTC, Microsoft Exchange Server, Mouse, OTCQB, Animal, Male, Protein, Unfolded protein response, Female, Disturbance, Antigen presentation, Toxicity, Melanoma, Therapy, Cancer, Vaccine

The use of AccuTOX® to reprogram these MSCs relies mainly on the induction of protein aggregation.

Key Points: 
  • The use of AccuTOX® to reprogram these MSCs relies mainly on the induction of protein aggregation.
  • In addition, our team found that at specific doses, AccuTOX® forms protein aggregates when mixed with tumor lysate, a process that pushes MSCs to degrade these intracellular complexes resulting in potent antigen presentation."
  • The ARM-002TM vaccine is even more potent, as it actually requires 10x less protein.
  • These results will set the target indication for the Phase I trials, and it also shows how versatile and adaptable the ARM-002TM anti-cancer vaccine is.

Feinstein Institutes’ Daniel A. Grande Named President-Elect of the International Cartilage Regeneration & Joint Preservation Society (ICRS)

Retrieved on: 
木曜日, 4月 18, 2024
Health, Hospitals, Other Health, Other Science, General Health, Research, Science, Education, FDA, Rheumatology, EVS, Microsoft Exchange Server, Intervertebral disc, Regenerative medicine, Seminal vesicles, Cartilage, Doctor of Philosophy, B cell, Meniscus, ICRS, Patient, Tissue engineering, Molecular medicine, 3D bioprinting, Medical research, Microsoft Access, Multimedia, Regeneration, Stem cell, Credit, Journal, Medical device

The International Cartilage Regeneration & Joint Preservation Society (ICRS) has named Daniel A. Grande, PhD, assistant vice president of research services and professor of molecular medicine and orthopedic surgery at The Feinstein Institutes for Medical Research , its new President-Elect.

Key Points: 
  • The International Cartilage Regeneration & Joint Preservation Society (ICRS) has named Daniel A. Grande, PhD, assistant vice president of research services and professor of molecular medicine and orthopedic surgery at The Feinstein Institutes for Medical Research , its new President-Elect.
  • View the full release here: https://www.businesswire.com/news/home/20240418363701/en/
    Feinstein Institutes’ Dr. Daniel A. Grande has been named the new president-elect of International Cartilage Repair Society.
  • (Credit: Feinstein Institutes)
    Dr. Grande, renowned for his significant contributions to cartilage repair and regeneration, will lead the ICRS in its mission to advance science and education in preventing and treating cartilage injuries.
  • "I am honored and excited to serve as the President-Elect of the International Cartilage Regeneration & Joint Preservation Society.

New Version of Netwrix 1Secure Accelerates Security Threat Detection and Safeguards Data Both On Premises And in the Cloud

Retrieved on: 
火曜日, 4月 23, 2024
Online, HIPAA, Accountability Act, General Data Protection Regulation, GDPR, Active Directory, Risk, Software as a service, Cybersecurity Maturity Model Certification, PCI, Microsoft, Entra, Microsoft Exchange Server, Infrastructure, Risk assessment, CMMC, Organization, Architecture

FRISCO, Texas, April 23, 2024 /PRNewswire/ -- Netwrix, a vendor that delivers effective and accessible cybersecurity to any organization, released a new version of its easy-to-use and fast-to-deploy IT auditing software-as-a-service (SaaS) solution, Netwrix 1Secure. It enables prompt detection of suspicious activities around data across the Microsoft 365 environment, Entra ID (formerly Azure AD), as well as Active Directory, and file servers.

Key Points: 
  • Netwrix 1Secure empowers customers to mitigate security risks before damage is caused, thanks to continuous security posture assessments.
  • Accelerated attack detection speeds up the response to threats and does not allow malicious actors to remain unnoticed.
  • The new version of Netwrix 1Secure includes the following enhancements:
    Improved security gaps identification and elimination with the Risk Assessment 2.0 module.
  • To learn more about the new version of Netwrix 1Secure, visit the product page .

New Version of Netwrix 1Secure Accelerates Security Threat Detection and Safeguards Data Both On Premises And in the Cloud

Retrieved on: 
火曜日, 4月 23, 2024
Online, HIPAA, Accountability Act, General Data Protection Regulation, GDPR, Active Directory, Risk, Software as a service, Cybersecurity Maturity Model Certification, PCI, Microsoft, Entra, Microsoft Exchange Server, Infrastructure, Risk assessment, CMMC, Organization, Architecture

FRISCO, Texas, April 23, 2024 /PRNewswire/ -- Netwrix, a vendor that delivers effective and accessible cybersecurity to any organization, released a new version of its easy-to-use and fast-to-deploy IT auditing software-as-a-service (SaaS) solution, Netwrix 1Secure. It enables prompt detection of suspicious activities around data across the Microsoft 365 environment, Entra ID (formerly Azure AD), as well as Active Directory, and file servers.

Key Points: 
  • Netwrix 1Secure empowers customers to mitigate security risks before damage is caused, thanks to continuous security posture assessments.
  • Accelerated attack detection speeds up the response to threats and does not allow malicious actors to remain unnoticed.
  • The new version of Netwrix 1Secure includes the following enhancements:
    Improved security gaps identification and elimination with the Risk Assessment 2.0 module.
  • To learn more about the new version of Netwrix 1Secure, visit the product page .

AdvisorVault Partners with Compliant Workspace Meeting Rule 17a-4 on Microsoft 365

Retrieved on: 
火曜日, 4月 16, 2024
Cloud, Online, OneDrive, Microsoft, Record, Microsoft Exchange Server, SharePoint, FINRA, Archive, Calendar, Migration, Video game

At the same time, firms must meet 17a-4 - that's why AdvisorVault has partnered with Compliant Workspace to get FINRA firms on the Microsoft Cloud properly.

Key Points: 
  • At the same time, firms must meet 17a-4 - that's why AdvisorVault has partnered with Compliant Workspace to get FINRA firms on the Microsoft Cloud properly.
  • Since FINRA doesn't care if member firms use the cloud to run their company (provided records are retained to meet SEC rule 17a-4), the best option for small FINRA firms is Microsoft 365.
  • To solve this, we partnered with Compliant Workspace - a Microsoft 365 service provider - giving our customers all the features getting on the Microsoft Cloud compliantly.
  • "We decided to partner with Compliant Workspace because customers needed to meet 17a-4 on Microsoft 365.

EQS-News: ERFOLGE VON DEFENCE BEI SEINEM ACCUTOX®-ARM(TM)-VAKZIN ZUR KREBSBEKÄMPFUNG FÜHREN ZUR ENTWICKLUNG EINES WIRKUNGSVOLLEN ARM-002(TM)-KREBSIMPFSTOFFS DER ZWEITEN GENERATION

Retrieved on: 
水曜日, 4月 10, 2024
Microsoft Exchange Server, Therapy, DTC, ADC, OTCQB, Generation, Spacecraft, News, Defense, Rope

Bei Tests als therapeutisches Vakzin bei einem Melanom-Modell führte ARM-002TM in Kombination mit dem Immuncheckpoint-Inhibitor Anti-PD1 in 80 % der Fälle zu einer vollständigen Reaktion.

Key Points: 
  • Bei Tests als therapeutisches Vakzin bei einem Melanom-Modell führte ARM-002TM in Kombination mit dem Immuncheckpoint-Inhibitor Anti-PD1 in 80 % der Fälle zu einer vollständigen Reaktion.
  • Darüber hinaus können entwickelte Immunzellen zu einem lang anhaltenden immunologischen Gedächtnis führen, das Patienten vor späteren Krebsrückfällen schützen kann.
  • Defence hat sich dafür entschieden, seinen AccuTOX®-Leitkandidaten zu testen, um einen Krebsimpfstoff der zweiten Generation zu entwickeln, da dieser bei einer intratumoralen Verabreichung in geringeren Dosierungen nachweislich die Antigenpräsentation in Krebszellen verbessert.
  • Der Kern der Defence Therapeutics-Plattform besteht in der ACCUM®-Technologie, die einen präzisen Transport von Impfantigenen oder ADCs in intakter Form zu den Zielzellen ermöglicht.

EQS-News: DEFENCE’S SUCCESSFUL RESULTS ON ITS  ACCUTOX® ANTI-CANCER ARMTM VACCINE CREATES A POTENT SECOND-GENERATION ANTI-CANCER ARM-002TM VACCINE

Retrieved on: 
水曜日, 4月 10, 2024
Antigen presentation, Neoplasm, Microsoft Exchange Server, DTC, Therapy, Vaccination, Melanoma, OTCQB, Antigen, Vaccine

When tested as a therapeutic vaccine in a melanoma cancer model, ARM-002TM leads to an 80% complete response when combined with the anti-PD-1 immune-checkpoint inhibitor.

Key Points: 
  • When tested as a therapeutic vaccine in a melanoma cancer model, ARM-002TM leads to an 80% complete response when combined with the anti-PD-1 immune-checkpoint inhibitor.
  • Compared to current anti-cancer strategies, vaccination can stimulate specific immune responses capable of potentially curing established tumors.
  • In addition, developed immune cells can lead to a long-lasting memory response capable of further protecting the patient from subsequent cancer relapses.
  • Although the ARMTM vaccine can effectively present antigens to responding T cells, the large amount of antigen preparation required to generate the cellular vaccine might represent challenges in the clinic.

Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals

Retrieved on: 
月曜日, 4月 8, 2024
SOC, CDMO, Orphan drug, Letter, Cell, Science, Bone marrow, Disease, Partnership, Caregiver, Hypoplastic left heart syndrome, Patient, Fast Track, Research, Microsoft Exchange Server, Standard of care, Security (finance), CLEAR, Surgeon, Regenerative medicine, FDA, BLA, Development, Pharmaceutical industry

MIAMI, April 08, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that the Company’s CEO, Wa’el Hashad, issued the following letter to Longeveron shareholders.

Key Points: 
  • MIAMI, April 08, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that the Company’s CEO, Wa’el Hashad, issued the following letter to Longeveron shareholders.
  • Today, I am excited to update you on our overall strategy, business objectives, approach to capital allocation, and 2024 key priorities and goals.
  • Our focus remains steadfast on raising the funds necessary to continue our operations and delivering transformative solutions to patients and creating sustainable value for our shareholders.
  • In 2024, we are focusing our efforts on two of our most promising programs: Hypoplastic Left Heart Syndrome (HLHS); and Alzheimer’s Disease.

BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS

Retrieved on: 
火曜日, 4月 9, 2024
Neurology, Neuroprotection, Element, Conference call, Institutional review board, Cerebrospinal fluid, Survival, Disease, ALS, SPA, Bone marrow, CSF, Data monitoring committee, Webcast, Patient, Protocol, Biomarker, Mortality, Microsoft Exchange Server, Stem cell, DMC, Screening, Agency, Safety, CAFS, Brainstorm, Therapy, Marketing, FDA, BLA, Neuroinflammation, Food, Pharmaceutical industry

NEW YORK, April 9, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it received written agreement from the U.S. Food and Drug Administration (FDA), under a Special Protocol Assessment (SPA), on the design for a Phase 3b trial of NurOwn® in amyotrophic lateral sclerosis (ALS). 

Key Points: 
  • (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it received written agreement from the U.S. Food and Drug Administration (FDA), under a Special Protocol Assessment (SPA), on the design for a Phase 3b trial of NurOwn® in amyotrophic lateral sclerosis (ALS).
  • The SPA agreement with the FDA validates the clinical trial protocol and statistical analysis of the planned Phase 3b trial of NurOwn, demonstrating their adequacy for addressing objectives that support a future BLA (Biologics License Application) in ALS.
  • We appreciate the Agency's engagement and guidance during the SPA process and look forward to moving forward with the study."
  • The Phase 3b trial (Study BCT-006-US) will be a two-part, multicenter, study designed to assess the efficacy and safety of NurOwn in patients with ALS.

Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy

Retrieved on: 
水曜日, 3月 20, 2024
CELU, Diagnosis, Shoulder, Biologics license application, Disease, Risk, Patient, Microsoft Exchange Server, Stem cell, IND, Facioscapulohumeral muscular dystrophy, Regenerative medicine, FDA, BLA, FSHD, Muscular dystrophy, Food, Pharmaceutical industry

FLORHAM PARK, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity”), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that it has submitted a request to the U.S. Food and Drug Administration (FDA) for orphan drug designation for its off-the-shelf, placental-derived cell therapy, PDA-002, for treating Facioscapulohumeral Muscular Dystrophy (FSHD).

Key Points: 
  • FLORHAM PARK, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“Celularity”), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that it has submitted a request to the U.S. Food and Drug Administration (FDA) for orphan drug designation for its off-the-shelf, placental-derived cell therapy, PDA-002, for treating Facioscapulohumeral Muscular Dystrophy (FSHD).
  • Orphan drug designation is a status given to drugs that show the potential to treat, prevent or diagnose serious or life-threatening diseases that affect fewer than 200,000 people in the U.S.
  • Earlier, Celularity received FDA Investigational New Drug Application clearance for PDA-002 in FSHD and plans to commence a phase 1/2 study in the second half of 2024.
  • The trial serves as an important component for submitting a Biologics License Application (BLA) to the FDA in the future as a potential treatment for FSHD and other types of muscular dystrophy.